An early phase 2 study with XELODA™ (capecitabine) in patients with metastatic breast cancer

被引：0
|
作者：
Saeki, T
Takashima, S
Terashima, M
Tabei, T
Enomoto, K
Tominaga, T
Kimura, T
Miura, S
Koyama, H
Konishi, Y
Oka, T
Naito, Y
Sonoo, H
Toge, T
Dohi, K
Nomizu, T
Taguchi, T
机构：
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
594
引用
收藏
页码：155 / 155
页数：1
相关论文
共 50 条
  • [31] A phase I study of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer
    Kalykaki, A.
    Agelaki, S.
    Kotsakis, A.
    Vamvakas, L.
    Bozionelou, V.
    Kalbakis, K.
    Androulakis, N.
    Georgoulias, V.
    Mavroudis, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] Capecitabine in elderly patients with metastatic breast cancer
    De Sanctis, Rita
    Quadrini, Silvia
    Longo, Flavia
    Lapadula, Vittoria
    Restuccia, Rossella
    Del Signore, Ester
    De Filippis, Lucilla
    Stumbo, Luciano
    Gori, Bruno
    Bianco, Vincenzo
    Speranza, Iolanda
    Basile, Maria Luisa
    Di Seri, Marisa
    TUMORI, 2012, 98 (03) : 303 - 307
  • [33] First line capecitabine (Xeloda®) chemotherapy for metastatic colorectal cancer (MCRC)
    Kovcin, V
    Krivokapic, Z
    Jesic, R
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 228 - 228
  • [34] Capecitabine (Xeloda®) in combination with oxaliplatin:: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors
    Díaz-Rubio, E
    Evans, TRJ
    Tabernero, J
    Cassidy, J
    Sastre, J
    Eatock, M
    Bisset, D
    Regueiro, P
    Baselga, J
    ANNALS OF ONCOLOGY, 2002, 13 (04) : 558 - 565
  • [35] Phase II study of capecitabine (Xeloda®) and concomitant boost radiotherapy in patients with locally advanced rectal cancer
    Krishnan, Sunil
    Janjan, Nora A.
    Skibber, John M.
    Rodriguez-Bigas, Miguel A.
    Wolff, Robert A.
    Das, Prajnan
    Delclos, Marc E.
    Chang, George J.
    Hoff, Paulo M.
    Eng, Cathy
    Brown, Thomas D.
    Crane, Christopher H.
    Feig, Barry W.
    Morris, Jeffrey
    Vadhan-Raj, Saroj
    Hamilton, Stanley R.
    Lin, Edward H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : 762 - 771
  • [36] Adding Xeloda (capecitabine) to docetaxel significantly improves survival and does not compromise quality of life in patients with metastatic breast cancer.
    Twelves, C
    Fumoleau, P
    Jones, SE
    Cherubini, R
    Foimtchuk, MJ
    Kroener, JF
    Martin, M
    Mennel, RG
    Tang, SC
    Van Hazel, GA
    Wigler, N
    Osoba, D
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 307 - 307
  • [37] A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours
    J P Delord
    J Y Pierga
    V Dieras
    F Bertheault-Cvitkovic
    F L Turpin
    F Lokiec
    I Lochon
    E Chatelut
    P Canal
    R Guimbaud
    D Mery-Mignard
    X Cornen
    Z Mouri
    R Bugat
    British Journal of Cancer, 2005, 92 : 820 - 826
  • [38] A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours
    Delord, JP
    Pierga, JY
    Dieras, V
    Bertheault-Cvitkovic, F
    Turpin, FL
    Lokiec, F
    Lochon, I
    Chatelut, E
    Canal, P
    Guimbaud, R
    Mery-Mignard, D
    Cornen, X
    Mouri, Z
    Bugat, R
    BRITISH JOURNAL OF CANCER, 2005, 92 (05) : 820 - 826
  • [39] A phase II trial of capecitabine (Xeloda®) in recurrent ovarian cancer
    Vasey, PA
    McMahon, L
    Paul, J
    Reed, N
    Kaye, SB
    BRITISH JOURNAL OF CANCER, 2003, 89 (10) : 1843 - 1848
  • [40] Phase II study of capecitabine (Xeloda®) in pts with advanced breast cancer (ABC), previously treated with anthracyclines and taxanes.
    Fumoleau, P
    Largillier, R
    Trillet-Lenoir, V
    Orfeuvre, H
    Extra, JM
    Lesimple, T
    Culine, S
    Montestruc, F
    Mouri, Z
    Gauducheau, CHR
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 285 - 285
12345